To investigate the efficacy of soy isoflavone on climacteric symptoms in postmenopausal women.
In this double-blind, randomized, placebo-controlled study, a total of 80 women (mean age = 55.1 years), who reported 5 or more hot flush episodes per day, were randomized to receive either 250 mg of standardized soy extract (Glycine max AT) a total of 100 mg/day of isoflavone (n = 40) or placebo (n = 40). Exclusion criteria included: contra-indication for hormone therapy (HT), chronic gastrointestinal diseases, and users of HT within the preceding 6-months. For 10-months, climacteric symptoms were evaluated using a score card and the menopausal Kupperman index. Compliance and safety were also assessed. At baseline and the end of the study, lipid and hormonal profiles, as well as vaginal, mammographic and ultrasonographic parameters were measured. The t-test, Wilcoxon test and ANOVA were used in the statistical analysis.
At baseline, the mean number of hot flushes was 9.6 ± 3.9 per day in the isoflavone group and 10.1 ± 4.9 in the placebo group (p > 0.05). After 10 months, there was a significant reduction in frequency of hot flushes among isoflavone users when compared to those on placebo (3.1 ± 2.3 and 5.9 ± 4.3, respectively) (p < 0.001). Kupperman index mean values showed a significant reduction in both groups. However, soy isoflavone was significantly superior to placebo, in reducing hot flush severity (69.9% and 33.7%, respectively) (p < 0.001). Endometrial thickness, mammography, vaginal cytology, lipids and hormonal profile did not change in both groups. No serious adverse event related to isoflavone treatment was reported.
The soy isoflavone extract exerted favorable effects on vasomotor symptoms and good compliance, providing a safe and effective alternative therapeutic for postmenopausal women.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Maturitas
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy.Arch Int Med. 2001; 161: 1161-1172
- Effect of dietary phytoestrogens on hot flushes: can soy-based proteins substitute for traditional estrogens replacement therapy?.Menopause. 2001; 8: 154-156
- The effects of dietary soy supplementation on hot flushes.Obstet Gynecol. 1998; 91: 6-11
- Effect of soy phytoestrogens on hot flashes in post-menopausal women with breast cancer: a randomized, controlled clinical trial.J Clin Oncol. 2002; 20: 1449-1455
- Treatment of menopause-associated vasomotor symptoms: position statement of NAMS.Menopause. 2004; 11: 11-33
- Isofalvone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies.Menopause. 2006; 13: 831-839
- Phytoestrogens and the menopause.Climateric. 1998; 1: 302-308
- Interaction of phytoestrogens with estrogen receptors α and β.Biol Pharm Bull. 2001; 24: 351-356
- Selective estrogen receptor modulators in reproductive medicine and biology.Obstet Gynecol Surv. 2000; 55: S21-S47
- Phytoestrogens and cardiovascular health.J Am Coll Cardiol. 2000; 35: 1403-1410
- Soy product intake and hot flashes in japanese women: results from community-based prospective study.Am J Epidemiol. 2001; 153: 790-793
- Clinical effects of a standardized soy extract in postmenopausal women: a pilot study.Menopause. 2000; 7: 105-111
- Vasomotor symptom relief by soy isoflavone extracts tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.Menopause. 2000; 7: 236-242
- Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study.Menopause. 2002; 9: 329-334
- Efficacy and safety of soy a phytoestrogen preparation derived from Glycine max (L.) Merr in climateric symptomatology: a multicentric, open, prospective and non-randomized trial.Phytomedicine. 2002; 9: 85-92
- Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT and placebo-controlled study.Menopause. 2004; 11: 400-404
- Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy.Maturitas. 2004; 48: 372-380
- Effects of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial.J Clin Oncol. 2002; 20: 1449-1455
- Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: the Soy Estrogen Alternative Study.Menopause. 2003; 10: 147-153
- A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients.Obstet Gynecol. 2003; 101: 1213-1220
- State-of-the-Science Conference statement: management of menopause-related symptoms.Ann Intern Med. 2005; 142: 1003-1013
- Isoflavones in human breast milk and other biological fluids.Am J Clin Nutr. 1998; 68: 1466S-1473S
- Isoflavones: food for thoughtful consideration.Menopause. 2003; 10: 189-190
- Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study.Maturitas. 2006; 53: 49-58
- Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis.Maturitas. 2006; 55: 203-211
- Oral estrogen replacement therapy verses placebo for hot flushes (Cochrane Review).Cochrane Database Sys Rev. 2001; 1 ([CD002978])
- Complementary and alternative therapies for the management of menopause-related symptoms.Arch Intern Med. 2006; 166: 1453-1465
- Nonhormonal therapies for menopausal hot flashes Systematic review and meta-analysis.JAMA. 2006; 295: 2057-2071
- Bioavailability of pure isoflavones in health humans analysis of commercial soy isoflavone supplements.J Nutr. 2001; 131: 1362-1375
- Pharmacokinetics of a slow-release formulation of soybean isoflavones in health postmenopausal women.J Agric Food Chem. 2005; 53: 1938-1944
- Bioavailability of phyto-oestrogens.Br J Nutr. 2003; 89: S45-S48
- Provisional recommended soy protein and isoflavone intakes for health adults: rationale.Nutr Today. 2003; 38: 100-109
- Health effects of phytoestrogens.Forum Nutr. 2005; 57: 100-111
- Isoflavones: their effects on cardiovascular risk and functions.Cur Opinion Lipidol. 2003; 14: 3-8
- The role of isoflavones in menopausal health: consensus opinion of NAMS.Menopause. 2000; 7: 215-229
- Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile.Am J Clin Nutr. 2005; 81: 397-408
- Meta-analysis of effects of soy protein intake on serum lipids.N Engl J Med. 1995; 333: 276-282
- The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women.J Clin Endocrinol Metab. 2002; 87: 118-121
- Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women.Fertil Steril. 2005; 83: 137-142
Published online: September 20, 2007
Accepted: August 25, 2007
Received in revised form: August 20, 2007
Received: March 29, 2007
© 2007 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.